Hydrogen inhalation therapy may ameliorate amyotrophic lateral sclerosis.
Yusuke Ichikawa, Bunpei Sato, Shin‐ichi Hirano, Yoshiyasu Takefuji, Fumitake Satoh · Medical Gas Research · 2023
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
The publication “Hydrogen inhalation therapy may ameliorate amyotrophic lateral sclerosis.” is organized in H2HUBB under the research focus hydrogen inhalation research study 2023. The publication is cited as Yusuke Ichikawa, Bunpei Sato, Shin‐ichi Hirano, Yoshiyasu Takefuji, Fumitake Satoh, Medical Gas Research, 2023. This uncontrolled human study examined Hydrogen inhalation therapy may ameliorate amyotrophic lateral sclerosis. The abstract describes Human participants; hydrogen delivered as hydrogen inhalation. The abstract reports: Amyotrophic lateral sclerosis (ALS) is a motor neuron disease, a neurodegenerative disorder characterized by sporadic and progressive degenerative loss of cell bodies of both…. This is an automated editorial draft based on the abstract and requires source review before publication.
Hydrogen inhalation research study 2023 overview
The main outcome was not fully reported in the available structured record and should be checked against the original source. Because this is human clinical evidence, relevance depends on participant selection, controls, sample size, treatment duration, adherence, outcome measures, and replication.
Study design and hydrogen intervention
Publication type: Uncontrolled human study. Evidence type: Human clinical evidence. Research model or population: Human participants. Blinding: Unknown. Control status: Unknown.
Delivery method: Hydrogen inhalation. Hydrogen flow rate: 200 mL/min. Dose or treatment amount: 200 mL.
Reported findings and scientific interpretation
For this hydrogen inhalation research study 2023, the study record reports the following: The abstract reports: Amyotrophic lateral sclerosis (ALS) is a motor neuron disease, a neurodegenerative disorder characterized by sporadic and progressive degenerative loss of cell bodies of both…
These findings should be interpreted as one piece of evidence rather than as a stand-alone medical conclusion. Results can be influenced by the research model, study design, treatment protocol, sample size, outcome selection, statistical methods, and whether the findings have been independently reproduced.
How this research record was prepared
H2HUBB organizes bibliographic details, study design information, intervention data, outcomes, limitations, and safety notes from the available scientific source. Automated classification supports database organization, but it does not replace critical reading of the complete paper. Source identifiers, evidence labels, and delivery-method fields are retained so readers can verify the record and compare it with related publications. A missing field means the information was unavailable or not reported in the structured source; it should not be treated as a negative finding.
Limitations, safety, and original source
Limitations: The abstract alone may not report all methodological limitations; full-text review is required.
Safety: Although he still uses a cane for safety, he has seen a definite improvement in his ability to walk.
This H2HUBB page is an educational research record, not medical advice. Review the original scientific source for the complete methods and results. Continue exploring the H2HUBB Molecular Hydrogen Research Library to compare evidence types, delivery methods, and related topics.